NEWS

Aktuell2019-12-13T16:39:37+01:00

News, trade fairs, press information

LTS and LIVZON enter into license and collaboration agreement to develop and commercialize ASENAPINE TTS

LTS AG and Livzon Pharmaceutical Group Inc. announced today that the companies have entered into an exclusive license and collaboration agreement. LTS grants to LIVZON and its Affiliates an exclusive royalty-bearing, sublicensable right and license to jointly develop with LTS the Asenapine TTS and commercialize the Asenapine TTS for the treatment of schizophrenia in China (including Hong Kong and Macau).

6.07.2020|Press Releases|